Emcure Pharmaceuticals (NSE:EMCURE) BreakoutThe Emcure Pharmaceuticals gave a breakout in a weekly timeframe from the zone(red zone) of 1595-1597. It is trying to give retest at the crucial juncture of 1595 again, but as the breakout was not supported by enough volumes hence, the stock will come back to the trendline (yellow line) and again try to give a breakout above 1595. If the breakout sustains on weekly timeframe and is supported by strong volumes, then the stock would rally 50% directly to 2400 price target. The target was chosen by measuring the April 2025 low to the current top of 1597 using price and data range indicator.
Fundamentally speaking, the company has all time high profits, all time high revenue, the margins have now normalized and as a part of earnings perspective the stock is a turnaround story. The company is expanding it's capacity at a stable rate, maintaining a healthy debt to equity ratio. The concerning part is accounts receivables (which has shot up to above 2000 levels in 2024 and the trend is increasing for under 6 month receivables) and inventory days which has although decreased from 293 in 2021 to 225 in 2025, but is still a concern. There is a sector tailwind for the Pharmaceutical sector in India due to the mention of making India a Biopharma manufacturing hub in the Union Budget of 2026, hence that gives an increase in probability of stock to perform well over 3-5 year time horizon.
Long
